Jasper Therapeutics, Inc. JSPR
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Jasper Therapeutics, Inc. (JSPR) is a healthcare company listed in the US with a market value of about $15M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -292%.
About Jasper Therapeutics
Jasper Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. It was profitable in 0 of the last 6 years in our data. Its share count rose by 425% over three years (dilution for shareholders).
Score: 0.2 / 5
Checks passed
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$76M | -$71M | -$64M | -$38M | -$31M | -$32M |
| Free cash flow | -$77M | -$63M | -$52M | — | -$34M | -$18M |
| EPS (diluted) | $-3.95 | $-4.89 | $-6.18 | $-10.33 | $-26.90 | $-51.70 |
| Net margin | — | — | — | — | — | — |
| ROIC | -1145.3% | -94.9% | -67.0% | -109.1% | -41.4% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $600.00, 4286% above the current price; targets range from $600.00 to $600.00; the consensus rating is “none”; expected EPS is $-6.90 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Jasper Therapeutics pay a dividend?
Not currently.
Is Jasper Therapeutics a good stock to buy?
We do not give buy or sell advice. Jasper Therapeutics scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.